With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

But, instead, studies have since found that they work in the brain. In fact, the molecular receptors for GLP-1 are sprinkled in many places around the body. They're found in the central nervous ...

Some 12% — or about 1 in 8 — people living in the U.S. have tried a GLP-1 drug, according to a survey by the Kaiser Family Foundation. And with that drug comes many dietary changes that need ...

Molecular glue degrader (MGD ... Sanofi bets on Resalis’ oligonucleotide RES-010 for obesity After missing out on the glucagon-like peptide 1 (GLP-1) obesity market, Sanofi SA is making a strategic ...

The enormous size of the chemical industry could make chemical stocks attractive to many investors. Large chemical stocks to consider include Air Products & Chemicals. Smaller chemical stocks with ...

With its multifaceted benefits, this probiotic is an essential component of the GlucoBoost formula, enhancing its overall effectiveness in promoting weight loss and health. One of the standout ...

New research shows a marked decline in weight-loss surgeries as GLP-1 meds like Wegovy or Zepbound surge in popularity Bariatric surgeries fell by more than a quarter between 2022 and 2023, as ...

A box containing injectable vials of the weight-loss drug Wegovy in Brighton, Mich. on June 8, 2023. (CYDNI ELLEDGE) ...

As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim their waistlines, a new report finds. Prescriptions of this GLP-1 class ...

Negotiations on the sale of a stake in GLP Pte’s China operations to Guangdong Holdings Ltd. have stalled due to disagreements over deal terms, according to people familiar with the situation.